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Abstract
Background
Bleeding and thromboembolic events (TE) are common complications following
HeartMate II (HMII) implantation. The aim of the study was to review our
experience related to bleeding and TE events in patients with a HMII and identify
factors associated with increased risk of these events.

Methods
We retrospectively reviewed 70 consecutive patients who received a HMII
between May 2006 and December 2011. The patients were followed for 12
months or until cardiac transplantation, device explantation or death. Major
bleeding was defined by INTERMACS criteria with intracranial bleeding events
added.
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Results
There were 48 bleeding events in 28 (40%) patients with gastrointestinal
bleeding (54.2%) being most common. Patients with bleeding events had
significantly higher average INR (p=0.04) and more chronic kidney
disease (p=0.03), although 43.8% of bleeding events occurred at an INR
<2. Twelve TE events occurred in 9 patients (12.9%), with ischemic
stroke the most common (75%). TE events were associated with young
age (p=0.04) and non-diabetes status (p=0.03) and were not associated
with average INR. There was no association of bleeding or
thromboembolism with gender, BMI, HMII speed, pulsatility index,
hypothyroidism, smoking history or INTERMACS profile at the time of
HMII implantation.
Conclusion
Different factors are associated with bleeding and TE events. The
appropriate target INR range for HMII patients should be chosen to
balance the risk between bleeding and TE events based largely on patient
factors.
Keywords
mechanical circulatory support; ventricular assist device; heart failure;
bleeding events; thromboembolic events
Abbreviations
HF = Heart Failure
NYHA = New York Heart Association
MCS = Mechanical Circulatory Support
HMII = HeartMate II
DM = Diabetes Mellitus
CKD = Chronic Kidney Disease
GFR = Glomerular Filtration Rate
vWF = von Willebrand Factor
HMWM = High Molecular Weight Multimers
PI = Pulsatility Index
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Introduction
The burden of heart failure (HF) continues to grow, with over 500,000 cases
annually1 and increasing numbers of hospitalizations. With pharmacological and
device-based therapies, 1 year mortality of HF patients with New York Heart
Association class (NYHA) III and IV has decreased from 50% in 1986 to less
than 15% in 2002.1-5 Despite these advances, many patients with advanced HF
continue to have severe symptoms.1
In the last 15 years, implantation of mechanical circulatory support (MCS) has
been demonstrated to prolong survival and improve quality of life. 1 Continuous
flow MCS can be used as destination therapy and bridge to recovery or
transplantation.6 The HeartMate II (HMII) by Thoratec Corporation, Pleasanton,
CA is one such continuous-flow device that has become the most commonly
used device for MCS in end-stage HF patients. However, there are still
substantial risks and complications during the implant period and with long term
HMII support.
Thromboembolic events occur with the use of HMII despite the use of
anticoagulation and antiplatelet therapies. This, in turn, is thought to contribute
to increased bleeding events in these patients. Indeed, bleeding complications
with the HMII are more common than thromboembolic events,7 with its incidence
varying widely between studies and influenced by the definition of bleeding used.
Bleeding was reported in 15.4% of patients in the HMII bridge to transplant trial. 8
Uriel et al in 2010 reported bleeding to occur in as high as 44.3% of the patients
receiving HMII.9 In patients who undergo mechanical valve replacement, where
a targeted INR is required, bleeding rates of only 2.68 to 4.6 events/100 patient
years are seen.10 In contrast, continuous flow MCS patients have been shown to
experience bleeding rates as high as 63 events/100 patient years.11 Therefore,
these events must be attributed to factors other than the use of anticoagulation
and antiplatelet therapies. A universal loss of high molecular weight multimer
(HMWM) has been reported in continuous flow MCS recipients.12 Development
of acquired von Willebrand syndrome due to loss of HMWM appears to be a
potential contributor to the bleeding tendencies in HMII recipients.13 In the
present study we review our experience related to the bleeding and
thromboembolic events in patients with HMII implantation and explore factors
associated with this increased risk.

Methods
Patients and Study Design
This study is a retrospective chart review of 70 consecutive subjects in whom a
HMII MCS was implanted between May 2006 and December 2011 at the
University of Wisconsin Hospital and Clinics, Madison, WI. The study was
approved and complied with all regulations of the University of Wisconsin
Institutional Review Board and the Veterans Affairs Research & Development
Committee. Baseline and demographic data were collected including age,
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gender, body mass index, HF etiology, NYHA class, history of diabetes mellitus
(DM) and chronic kidney disease (CKD). CKD was defined as glomerular
filtration rate (GFR) <60 mL/min/1.73 m2 for at least 3 months. Subjects were
categorized by whether HMII was placed as a bridge to transplantation, bridge to
candidacy or as destination therapy. The subjects were followed every 6-12
weeks for 12 months or until cardiac transplantation, device explantation or
death. Major bleeding episodes were defined by the INTERMACS criteria14 as
any internal or external bleeding event that results in death, hospitalization,
reoperation or red blood cell transfusion (greater than or equal to 4 units within
first 7 days post implant and any number of units after 7 days post implant).
Intracranial bleeding was also included as a major bleeding episode in this
analysis, although it was classified as a neurological event in INTERMACS.
Thromboembolic events were defined by any arterial thromboembolic events
including ischemic stroke and confirmed pump thrombosis. The HMII pump
speed, pulsatility index (PI), flow and power were recorded at the time of the
implantation, at 1, 2 and 3 months post implantation and every 3 months
thereafter.
Clinical assessment and echocardiographic parameters were used to adjust the
HMII speeds to optimize cardiac output, achieve adequate left ventricular
decompression, avoid suction events, maintain target pulsatility index and
provide aortic valve opening every 2-3 beats when possible. Pump speed was
set between 8600 and 10000 rotations per minute (rpm) according to these
factors. All patients were on a HF medication regimen titrated to maintain mean
blood pressures <85 mmHg and optimize perfusion based on clinical
assessment.
Anticoagulation therapy
Low dose aspirin and anticoagulation therapy with warfarin was started on postoperative day 2 or 3. INR was maintained between 2 and 3. No post-operative
heparin was given. For purposes of this study patients’ INRs were recorded at 1,
2 and 3 months’ post hospital discharge, every 3 months thereafter and when
patients presented with a bleeding or a thromboembolic event. INR at the time of
bleeding and thromboembolic events was recorded. Also, average INR was
calculated by taking the mean of all the INR values from the time the INR first
became therapeutic after the HMII placement till the bleeding event.
Statistical Analysis
Statistical analysis was performed using SPSS version 19.0. Continuous data
were compared using the t-test and presented as mean and standard deviation.
Categorical data were analyzed using the chi square or the Fischer exact test.
Results were considered statistically significant for a p value less than 0.05. We
also used repeated measure analysis with binary outcome to test the effect of
average PI on bleeding events adjusting for months since implant, age and
gender. Using a binary outcome analysis, we model the odds of a “success”
(bleeding event), p(x)/(1-p(x)). The slope=b means that the odds increase
multiplicatively by exp(b) for every one-unit increase in the predictor, PI.
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Results
Demographics
The baseline characteristics of the population are shown in Table 1. The
INTERMACS profiles of the patients are shown in Figure 1.
Table 1. Baseline Characteristics of the Study Population

Average follow up was 238+/-168 days with a total of 45.6 patient-years of follow
up. Fifteen patients (21.4%) completed 12 months of post device implantation
follow up without transplantation, device explant or death; 39 (55.7%) underwent
cardiac transplantation and 15 (21.4%) died. One patient developed HMII
dysfunction with mediastinal hematoma after a fall, requiring device explantation,
and was not re-implanted due to recovery of left ventricular function.
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Figure 1 Percentage of study patients (y axis) in various INTERMACS
profiles (x axis)
Bleeding
There were 48 bleeding events in 28 patients. Six of these (21.4%) occurred in
women. Average age was 56.3+/-9.9 years. Blood transfusion was necessary in
27 (56.3%) bleeding events with an average of 2.1+/-2.6 units of packed red cells
per event (range of 0-12 units, interquartile range of 0-4 units with 0 and 4 the
25th and 75th percentile respectively and median of 2 units per event).
Gastrointestinal bleeding was the most common bleeding event. Intracranial
bleeding occurred in 6 patients and had a case fatality rate of 50%. Traumatic
bleeding occurred in four patients causing mediastinal hematoma, lower
extremity hematoma, hemothorax and acute subdural hematoma occurring in
one patient each. There were no post-surgical bleeding events. Five bleeding
events resulted in death and 5 required major surgical interventions (laparotomy
in 2 and craniotomy, thoracotomy and lower extremity debridement in 1 patient
each). Bleeding events and their outcomes are summarized in Table 2.
Many bleeding events, 21 of 48 (43.8%), occurred at an INR level of less than 2;
19 (39.5%) at INR between 2 and 3 and 8 (16.7%) at an INR greater than 3
(Figure 2).

Table 2. Bleeding Events and their Outcomes
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Figure 2 Percentage of bleedings and thromboembolic events
(y axis) against INR (x axis)
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Table 3 shows clinical characteristics of patients with bleeding compared to those
without. Patients with bleeding events tended to be older and had significantly
higher average INR than patients without bleeding events. Eighteen of 28
(64.2%) patients with bleeding events had CKD as compared to 16 of 42 (38.1%)
without bleeding events (p=0.03). Greater proportion of females experienced a
bleeding event as compared to males (46% vs 38.6%), although this result was
not statistically significant.

Table 3. Comparison of Characteristics of Patients with and without
Bleeding Events

Bleeding was not associated with HMII speed, body mass index pre HMII
implantation, HF etiology, DM, hypothyroidism, smoking status or pre-operative
INTERMACS profile. We also analyzed bleeding events with the average home
PI and PI recorded at each clinic visit. Bleeding events were not associated with
average home PI (slope of - 0.04 +- 0.29, p=0.88) or the clinic PI value (slope of
0.12+-0.35, p=0.72). Average time to a bleeding event was 109 +/- 115 days
with 34 (70.4%) events occurring within 4 months of device implantation (Figure

3).
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Figure 3: Cumulative percentage of bleeding and thromboembolic
events (x axis) over time in months (y axis)
Thromboembolic Events
There were 12 thromboembolic events in 9 patients. All were males except one.
Most events, 8 of 12 (66.7%), occurred at an INR of <2 and 4 (33.3%) at an INR
between 2 and 3. None of the thromboembolic events occurred with INR >3
(Figure 2). Ischemic stroke was the most common thromboembolic event (Table
4).

Table 4. Thromboembolic Events and their Outcomes
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Table 5 presents the clinical characteristics of patients with and without
thromboembolic events. Patients who had thromboembolic events were
significantly younger that those who did not. Thromboembolic events were not
found to be associated with body mass index, HMII speeds, average INR, HF
etiology, hypothyroidism, smoking history, CKD, gender or preoperative
INTERMACS profile. Non-diabetics comprised 88.9% (8 out of 9) of the patients
who had a thromboembolic event as compared to 49.2% who did not, suggesting
thromboembolic events to be more common among non-diabetics (p=0.03).
Average time to a thromboembolic event was 130+/-140 days with 7 out of 12
events (58.3%) occurring in less than 90 days (Figure 3).

Table 5. Comparison of Characteristics of Patients with and without
Thromboembolic Events

Discussion
The HMII is currently the most widely used long term mechanical circulatory
support device, with more than 7,000 implantations and more than 3,000 patients
on support.15 It is associated with significant improvement in 2 year survival free
of stroke and device failure compared with pulsatile MCS.7 Advantages of HMII
include its reduced size, increased durability, ease of implantation, and reduced
infections.9 However, complications can accompany the use of HMII, the most
significant of which are bleeding and thromboembolic events.
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With varying definitions of bleeding, bleeding rates as high as 44.4% have been
reported in patients with HMII.9 In our study, 40% of the patients had one or
more bleeding events. Using a similar definition of bleeding as in our study,
Bunte et al16 reported occurrence of bleeding in 58% of the population. Notably
this study also had a high rate of post-operative bleeding and classified anemia
of undetermined source as a bleeding event. The average INR in the bleeding
population in our study was significantly higher than the non-bleeding population,
even though both values were in the therapeutic range of 2-3. This reinforces
that a higher level of anticoagulation contributes to bleeding events. Keeping
INR in the low therapeutic range may decrease the frequency of bleeding.
However, nearly half the bleeding events in our population occurred at INR of <2.
This suggests that average INR over a period of time may be a better marker of
bleeding than the INR at the time of the event. Patients on chronic long term
anticoagulation secondary to mechanical valve replacement or atrial fibrillation
and HF patients on anticoagulation have far lower bleeding rates than those
observed in continuous flow MCS populations. The WATCH trial (Warfarin and
Antiplatelet Therapy in Heart Failure Trial)17 that examined the role of
anticoagulation in HF patients revealed rates of bleeding on warfarin at 5.2%,
significantly lower than observed in our series. Similar results were reported in
the WASH (Warfarin/Aspirin Study in Heart Failure) and HELAS (Heart Failure
Long Term Antithrombotic Study) studie.18,19 These data suggest presence of
additional factors contributing to bleeding events in MCS patients.
Recent studies have supported a contribution of acquired von Willebrand
deficiency to bleeding events in continuous flow MCS patients.9,20-22 HMII
patients experience altered physiology due to the high shear stress associated
with blood flow through the impeller. This shear stress is hypothesized to result
in vWF conformation changes that lead to proteolysis and cleavage of the
HMWM by ADAMTS13.23 Uriel et al9 and Meyer et al22 reported decreased or
absent HMWM forms of vWF in all patients with HMII in their studies. Similar
results were produced in a recent study that showed decrease of 30+/-14% of
HMWM of vWF in patients with HMII compared to normal plasma levels.24
However, not all these patients had bleeding events, possibly suggesting a
multifactorial etiology.
Gastrointestinal bleeding was the most common cause accounting for bleeding in
22.3% of all the study patients. This is in accordance with the other studies.9,25,26
Although the most common etiology, only 1 patient died secondary to a major
gastrointestinal bleed. Gastrointestinal bleeding likely results from factors
besides anticoagulant therapy and acquired vWF deficiency. Older patients tend
to have more colonic polyps, increasing the risk of colonic bleeding. In patients
with HMII the left ventricle is relatively decompressed, with minimal opening of
the aortic valve creating flow patterns similar to those with aortic stenosis. Heyde
et al27 suggested that the abnormal pulse wave associated with aortic stenosis
may cause distention of the sub-mucosal venous plexuses of the gastrointestinal
tract and eventually lead to angiodysplasia and arteriovenous malformations.27
Cessation of gastrointestinal bleeding has been reported in continuous flow MCS
patients after cardiac transplantation.28
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Most bleeding events (70.4%) occurred in the first 4 months of HMII implantation.
Bunte et al16 also showed cumulative incidence of bleeding peaking within the
first 3 months. There was no post-surgical bleeding requiring re-sternotomy in
these patients, although the reported incidence of this varies from 10-30% in
literature.7,29-31 Previous studies have suggested age as an important risk factor
for bleeding after MCS.9,26,30 Boyle et al32 determined age >65 a risk factor for
increased bleeding in this population. Uriel et al9 showed that the risk of bleeding
for a patient >66 years was 65%. Our study had only 5 patients (7.1%) who were
greater than 65 years of age with a non-significant trend toward increased
bleeding in older patients. In our study, bleeding events were more common in
patients with CKD. Only 3 patients (10.7%) had 6 bleeding events while on some
form of hemodialysis (chronic hemodialysis or continuous veno-venous
hemofiltration). Administration of heparin or sodium citrate during the
hemodialysis can contribute to bleeding, however, does not explain association
of bleeding with CKD as the proportion of patient on hemodialysis was small.
Bleeding can also be attributed to platelet dysfunction due to decreased platelet
aggregation and impaired platelet adhesiveness in CKD.33 The impairment in
platelet adhesiveness may result at least in part from intrinsic dysfunction of
glycoprotein IIb/IIIa, a platelet membrane glycoprotein that plays a major role in
platelet aggregation and adhesion by interacting with fibrinogen and vWF.34-36
Boyle et al32 reported female gender as a risk factor for bleeding events. In our
study although the incidence of bleeding was higher in females, this result was
not statistically significant, likely due to a small proportion of female population in
the study. We also hypothesized that increased HMII speed would be associated
with increased bleeding events. Increased speed would decompress the left
ventricle and result in decreased opening frequency of the aortic valve with flow
patterns similar to those observed in aortic stenosis and predisposing to
gastrointestinal arteriovenous malformations. Higher speeds would also
theoretically expose red cells to increased shear stress and increase severity of
acquired von Willebrand syndrome. However, in our study there was no
association of bleeding with HMII speeds.
We examined the association of bleeding with PI. It has been hypothesized that
decreased PI may lead to arteriovenous malformations and thus an increased
risk of bleeding through a similar mechanism to the Heyde syndrome in aortic
stenosis.27 Wever-Pinzon et al37 reported low PI to be associated with increased
risk of non-surgical bleeding during the first 3 months after implantation of HMII.
We, however, did not find any association between bleeding events and PI.
Recent data suggests that the bleeding risk of continuous flow MCS support may
be offset by minimizing the use of anti-coagulation.38 However, pump thrombus
and embolic cerebrovascular accidents remain a concern. In our study, the level
of INR was not statistically different in patients with and without thromboembolic
events. However, 66.7% of all the thromboembolic events occurred at INR of
less than 2 and none of the events occurred at an INR greater than 3. This
sheds light on the efficacy of anticoagulant therapy to prevent these events in
patients with the HMII. Boyle et al8 reported thromboembolic events in 3.3% of
the population with HMII, a lower rate than that found in our study. Similar lower
The VAD Journal: http://dx.doi.org/10.13023/VAD.2016.07
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rates have been reported in comparable cohorts in other studies.15,39 it is also
important to note that the advanced heart failure population has an inherent risk
of thromboembolic stroke. In the Randomized Evaluation of Mechanical
Assistance in Treatment of Chronic Heart Failure (REMATCH) trial, patients
assigned to optimal medical therapy had a yearly stroke rate of 5.2%. 5
A recent study found significantly increased incidence of thrombotic
complications in females;32 however, in our study gender was not associated with
thromboembolic events. Interestingly, in our study, thromboembolic events were
more common in younger patients and in non-diabetics. In clinical experience,
younger patients are seen to be less compliant with medications and also have
better inflammatory and clotting cascades that may account for this result.
Association of thromboembolic events with non-diabetes status is curious but this
could be a cofactor as young patients are less likely to have underlying diabetes
mellitus. It appears in our data and the literature that younger patients are more
likely to have thromboembolic events and older patients more likely to bleed; a
possible implication would be that INR goals be tailored to patient age. However,
further studies are needed to confirm this hypothesis.
Recently, Starling et al reported occurrence of pump thrombosis to be 7.5%
during 12 months of support, and 12.3% during 24 months of support with HMII.40
In our study, only one patient developed pump thrombosis (1.4%).

Conclusion
Our study confirms that thrombotic events in patients implanted with continuous
flow MCS are significantly overshadowed by the frequency of hemorrhagic
events. We did not find any association of the bleeding or thromboembolic
events with HMII speed, body mass index, HF etiology, hypothyroidism, smoking
status or pre-operative INTERMACS profile. Bleeding events are associated with
chronic kidney disease and the level of anticoagulation, with average INR
appearing to be an important factor than the INR at the time of the event. The
appropriate target INR range for HMII patients should be chosen to minimize the
risk of devastating hemorrhagic and ischemic strokes and reduce the incidence
of major bleeding. Since most thromboembolic events in our study occurred at
INR <2 and the average INR in the non-bleeding population was 2.09 (compared
to 2.47 in the bleeding population), keeping INR values in the lower therapeutic
range seems to be a reasonable strategy. However, INR management may best
be tailored on an individual basis.
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